Bleeding risk in patients with atrial fibrillation treated with combined anti-platelet and NOAC therapy

27 August 2021 (08:00 - 20:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Associate Professor Yoo Ri Kim

Chonnam National University Hospital, Gwangju (Korea (Republic of))

57 More presentations in this session

Presentation thumbnail

Efficacy of propafenone vs. amiodarone in pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm: a pooled meta-analysis of 9 randomized controlled trials

Doctor J. Borovac (Split, HR)

Abstract Slides

Presentation thumbnail

The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus

Doctor A. KANWAL (Valhalla, US)

Abstract Slides

Presentation thumbnail

Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using the antiarrhythmic drug niferidil. First results of clinical use.

Doctor K. Dzaurova (Moscow, RU)

Abstract Slides

Presentation thumbnail

The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis

Mrs A. Boulmpou (Nijmegen, NL)

Abstract Slides

Presentation thumbnail

Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis

Mrs A. Boulmpou (Nijmegen, NL)

Abstract Slides

Access the full session

Session thumbnail

Pharmacology and pharmacotherapy e-posters

The Event

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET

You may be interested in

Webinar

Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients

Congress Presentation

Antithrombotic therapy in diabetes

Congress Presentation

Contemporary thrombosis management -- state of the state

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources